Scalp Cooling for the Prevention of Chemotherapy-Induced Alopecia

FDA‑approved scalp hypothermia devices are considered reasonable and necessary to prevent chemotherapy‑induced alopecia in patients receiving chemotherapy for solid tumors. Use is contraindicated in pediatric patients, those with certain cancers (CNS malignancies, specified lung and skin cancers, hematologic malignancies), patients undergoing bone marrow ablation or skull irradiation, those with scalp metastases or cold‑sensitivity disorders, and patients with severe liver or renal impairment that may prevent drug clearance.

"Use of an FDA-approved scalp hypothermia device for prevention of chemotherapy-induced alopecia is considered reasonable and necessary for patients receiving chemotherapy for solid tumors."

Sign up to see full coverage criteria, indications, and limitations.